Regenerex

Biotechnology ResearchKentucky, United States2-10 Employees

Regenerex is a biotechnology research company located at 201 East Jefferson Street, Suite 110b, Louisville, Kentucky 40202, United States, focused on developing cellular therapies for selected organ transplant and autoimmune conditions. It is described as a late clinical stage company conducting an ongoing Phase 2 study of its proprietary allogeneic cell therapy product, FCRx, with the aim of achieving long-term durable tolerance and reducing the burden of chronic immunosuppression. FCRx is a platform technology with potential to treat various indications, including organ transplants, autoimmune diseases, red blood cell disorders, and inherited metabolic disorders, without myeloablative conditioning and without the toxicities associated with standard hematopoietic stem cell transplants. The FDA has granted clearance to proceed with several INDs and IDEs for FCRx, and the most mature indication involves a living donor kidney transplant, which has Phase III FDA clearance to proceed and Orphan Drug Status. In 2019, Regenerex LLC announced a financing event and subsequently renamed itself Talaris Therapeutics; the company lists 2-10 employees and maintains a website at regenerex.com.

Sign up for free to view info

Email Format Employee directory